VCT220
Phase 2Small molecule
VCT220 is one of 45 small molecule programs targeting Renal Impairment. It is currently in Phase 2.
2
Indications
5
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Nitrostat
VViatris Specialty LLC
Phase 3
Alka-Seltzer
AAbbott
Phase 3
Minocycline /d
UUniversity of Florida
Phase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
VCT220
VVincentage Pharma Co., Ltd
Phase 2
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VCT220. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVincentage Pharma Co., Ltd